Sign In | Join Free | My cnltr.com
cnltr.com
Products
Search by Category
Home > Traditional Therapies >

Rimonabant Oral Anabolic Steroids Anorectic Antiobesity Drug CAS 168273-06-1

Categories Oral Anabolic Steroids
Brand Name: ChineseHormone
Model Number: CAS 168273-06-1
Certification: GMP, ISO 9001, USP
Place of Origin: China
MOQ: Free samples Available
Price: negotiated
Payment Terms: Western Union, MoneyGram, T/T, Bitcoin
Supply Ability: 500-1000 kg / month
Delivery Time: 3-7 working days
Packaging Details: as your required
MW: 463.787
MF: C22H21Cl3N4O
Appearance: White crystalline powder
Water Solubility: 0.002 mg/mL
Alias: SR141716, Acomplia, Zimulti
Shipment:: FedEx, TNT, EMS, DHL.UPS,EUB
  • Haven't found right suppliers
  • Our buyer assistants can help you find the most suitable, 100% reliable suppliers from China.
  • And this service is free of charge.
  • we have buyer assistants who speak English, French, Spanish......and we are ready to help you anytime!
  • Submit Buying Request
    • Product Details
    • Company Profile

    Rimonabant Oral Anabolic Steroids Anorectic Antiobesity Drug CAS 168273-06-1

    Rimonabant Oral Anabolic Steroids Anorectic Antiobesity Drug CAS 168273-06-1


    CAS number168273-06-1

    WeightAverage: 463.787
    Monoisotopic: 462.078094435

    Chemical Formula :C22H21Cl3N4O


    Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that has been withdrawn from the market due to potentially serious side effects. It was approved for use in Europe and other countries, but never approved in the United States. Rimonabant is an inverse agonist for the cannabinoid receptor CB1. It has also been shown to be a μ-opioid receptor antagonist(possibly the contributing factor in its reported dysphoric qualities). Its main effect is reduction in appetite.


    Uses/potential uses


    Obesity


    In a 2006 (2 year) study reported in JAMA, "Compared with the placebo group, the 20 mg of rimonabant group produced greater mean (SEM) reductions in weight (-6.3 [0.2] kg vs -1.6 [0.2] kg; P<.001), waist circumference (-6.1 [0.2] cm vs -2.5 [0.3] cm; P<.001), and level of triglycerides (percentage change, -5.3 [1.2] vs 7.9 [2.0]; P<.001) and a greater increase in level of high-density lipoprotein cholesterol (percentage change, 12.6 [0.5] vs 5.4 [0.7]; P<.001)."


    Smoking cessation


    Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers.


    Initial results apparently suggest rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi that, without additional studies, rimonabant cannot be approved in the United States for smoking cessation therapy. According to a Cochrane Collaboration review in 2007, rimonabant "may increase the odds of quitting approximately 11/2-fold".


    Addiction behaviors


    Rimonabant reduced resumption of cocaine-seeking responses triggered by two of the three most common triggers of relapse in humans: priming and cues. It may also reduce ethanol and opiate-seeking behavior.


    Short-term memory


    Tetrahydrocannabinol (THC) is known to impair short-term memory. It was therefore hypothesised that rimonabant may reduce or inhibit the atrophic effects of cannabinoids. Indeed, in animal studies, it significantly improved the ability of rats to encode information into short-term memory.


    Blockage of cannabis effects


    Rimonabant blocks the psychoactive and some of the cardiovascular effects of Δ9-tetrahydrocannabinol (THC) in humans without affecting the pharmacokinetics. Rimonabant has been described colloquially as "reverse marijuana", having a depressing effect on appetite inverse to the increased appetite created by cannabinoids.


    Predicted Properties


    PropertyValueSource
    Water Solubility0.002 mg/mLALOGPS
    logP5.47ALOGPS
    logP5.91ChemAxon
    logS-5.4ALOGPS
    pKa (Strongest Acidic)12.42ChemAxon
    pKa (Strongest Basic)1.68ChemAxon
    Physiological Charge0ChemAxon
    Hydrogen Acceptor Count3ChemAxon
    Hydrogen Donor Count1ChemAxon
    Polar Surface Area50.16 Å2ChemAxon
    Rotatable Bond Count4ChemAxon
    Refractivity122.83 m3·mol-1ChemAxon
    Polarizability47.96 Å3ChemAxon
    Number of Rings4ChemAxon
    Bioavailability1ChemAxon
    Rule of FiveYesChemAxon
    Ghose FilterYesChemAxon
    Veber's RuleYesChemAxon
    MDDR-like RuleYesChemAxon


    Quality Rimonabant  Oral Anabolic Steroids Anorectic Antiobesity Drug CAS 168273-06-1 for sale
    Send your message to this supplier
     
    From:
    Enter your email please.
    To: Hengyang Desen Biotechnology Co., Ltd.
    Subject:
    Message:
    Characters Remaining: (0/3000)
     
    Inquiry Cart 0